

|  |            |
|--|------------|
| <b>Associate Editors</b>   | <b>vii</b> |
| <b>Contributors</b>  | <b>ix</b>  |
| <b>Introduction</b>  | <b>1</b>   |
| By Michael S. Kappy, Lewis Barness, Leslie Barton,<br>Enid-Gilbert Barness, and Moritz Ziegler                             |            |
| <b>Joseph W. St. Geme, Jr., MD: Optimist, Scholar,<br/>Visionary, and Role Model (April 10,<br/>1931-October 11, 1986)</b> | <b>3</b>   |
| By Joseph W. St. Geme, III   |            |
| <b>Proteomics in Pediatric Research and Practice</b>   |            |
| By Stephen W. Hunsucker, Frank J. Accurso, and<br>Mark W. Duncan   |            |
| The proteome and proteomics  | 10         |
| What can proteomics offer clinical medicine?   | 10         |
| Proteomic methods  | 12         |
| Protein profiling strategies—discovery, validation, routine<br>testing all in one  | 13         |
| Two-dimensional gel based approaches—discovery alone   | 14         |
| Liquid chromatography—tandem mass spectrometry<br>approaches—discovery alone   | 16         |
| Arrays—some discovery, some validation, some routine testing   | 18         |
| Limitations of existing proteomic methods: some additional<br>considerations   | 20         |
| The next frontier: focused attention to co- and post-translational<br>events and the complexity of the proteome            | 21         |
| One-gene yields many products: site-specific enzymatic cleavage<br>of a single gene product                                | 21         |
| Alternative splicing of a gene product   | 23         |
| Some common modifications of amino acids   | 23         |
| Protein modifications and disease  | 23         |

## Advances in Pediatric Pharmacology, Therapeutics, and Toxicology

By Ian M. Paul

|  |    |
|--|----|
| Symptomatic care   | 30 |
| Fever  | 30 |
| Cough and cold   | 31 |
| Sore throat  | 32 |
| Vomiting and diarrhea  | 32 |
| Infectious diseases  | 32 |
| Streptococcal pharyngitis                                    | 32 |
| Acute otitis media and otitis externa                        | 33 |
| Pneumonia  | 33 |
| Urinary tract infection                                      | 34 |
| Infectious diarrhea  | 34 |
| Tinea capitis  | 34 |
| Hepatitis C  | 34 |
| Pulmonary  | 35 |
| Asthma prevention  | 35 |
| Inhaled corticosteroids versus montelukast for asthma        | 35 |
| Long-acting beta agonists                                    | 36 |
| Neurology  | 36 |
| Seizures   | 36 |
| Migraines  | 36 |
| Oncology   | 37 |
| Cardiology   | 37 |
| Hypertension   | 37 |
| Kawasaki syndrome  | 37 |
| Dermatology  | 38 |
| Atopic dermatitis  | 38 |
| Acne   | 38 |
| Obesity and polycystic ovary syndrome                        | 39 |
| Adolescent medicine and gynecology                           | 40 |
| Contraceptives   | 40 |
| Emergency contraception                                      | 40 |
| Psychiatry   | 41 |
| Attention-deficit hyperactivity disorder                     | 41 |
| Depression   | 42 |
| Pervasive developmental disorder                             | 42 |
| Neonatology  | 43 |
| Drug development and medication use                          | 43 |
| Bronchopulmonary dysplasia                                   | 43 |
| Hypotension  | 44 |
| Neonatal infections  | 44 |
| Neonatal pain  | 44 |
| Necrotizing enterocolitis                                    | 45 |
| Toxicology and transfer of drugs between mothers and infants | 45 |
| Selective serotonin reuptake inhibitors                      | 45 |
| Congenital malformations                                     | 46 |

|  |    |
|--|----|
| Transfer of anesthetics through human milk | 46 |
| Antibiotic adverse effects                 | 47 |
| Acetaminophen overdose                     | 47 |
| Clonidine overdose                         | 47 |

## **Advances in Idiopathic Scoliosis in Children and Adolescents**

By Gerard L. Glancy

|  |    |
|--|----|
| Etiology of idiopathic scoliosis             | 55 |
| Detection of scoliosis                       | 55 |
| Types of idiopathic scoliosis                | 57 |
| Infantile scoliosis                          | 57 |
| Juvenile scoliosis                           | 57 |
| Adolescent scoliosis                         | 59 |
| Treatment of adolescent idiopathic scoliosis | 59 |
| Advances in surgical correction of scoliosis | 61 |
| Summary                                      | 64 |

## **Evaluation of the Quality of Care in Congenital Heart Surgery: Contribution of the Aristotle Complexity Score**

By Francois Lacour-Gayet, Jeffrey P. Jacobs, David R. Clarke, Bohdan Maruszewski, Marshall L. Jacobs, Sean M. O'Brien, and Constantine Mavroudis

|  |    |
|--|----|
| Why evaluate quality of practice?  | 68 |
| Quality of care evaluation must look at multiple outcomes  | 68 |
| Operative mortality  | 68 |
| Operative morbidity  | 69 |
| Long-term functional results   | 71 |
| Cost   | 71 |
| Patient and family satisfaction  | 71 |
| The five different categories of performance   | 71 |
| The five components of the evaluation of the quality of care   | 71 |
| A common language: the international nomenclature  | 72 |
| A data collection system: the registry   | 72 |
| A data verification process  | 72 |
| A multisocietal congenital heart diseases network  | 73 |
| A fair method to compare outcomes between centers and surgeons   | 74 |
| The Aristotle complexity score   | 74 |
| Risk depends on performance. Complexity, defined as the sum of the operative mortality, the operative morbidity and the technical difficulty, does not | 74 |
| Why include technical difficulty in the equation?  | 75 |
| The initial period: complexity based on subjective probability   | 76 |
| Two principles of the aristotle complexity score   | 77 |
| Limitations of the aristotle score   | 79 |
| Validations of the Aristotle scores  | 80 |

|   |    |
|---|----|
| The second period: complexity based on indices calculated<br>on observed data | 80 |
| Future developments   | 81 |

**Advances in the Diagnosis and Treatment  
of Osteoporosis**

By Jill Simmons, Phil Zeitler, and Joel Steelman

|  |     |
|--|-----|
| Pediatric-specific background  | 85  |
| Contributions to bone mass   | 86  |
| Osteogenesis imperfecta  | 91  |
| Gastrointestinal disease   | 91  |
| Endocrine disorders  | 91  |
| Oncologic and/or organ transplants   | 93  |
| Anorexia nervosa/malnutrition  | 93  |
| Other disorders  | 94  |
| Evaluation of bone health  | 94  |
| Dual-energy X-ray absorptiometry   | 94  |
| Other measurements of bone density   | 95  |
| Quantitative CT  | 95  |
| Peripheral quantitative CT   | 96  |
| Quantitative ultrasound  | 96  |
| Evaluation of fracture risk in pediatric patients  | 96  |
| Evaluation of pediatric patients with low bone mass<br>with or without fragility fractures | 97  |
| Treatment  | 98  |
| Bisphosphonate therapy   | 98  |
| Treatment protocols for bisphosphonates  | 100 |
| Osteogenesis imperfecta  | 101 |
| Chronic glucocorticoid use   | 102 |
| Hypotonia or nonambulatory status  | 103 |
| Bisphosphonate adverse effects   | 103 |
| Monitoring of bisphosphonate therapy   | 104 |
| Anabolic agents  | 104 |
| Growth hormone/insulin-like growth factor  | 105 |
| Parathyroid hormone  | 106 |
| Strontium  | 106 |
| Other potential anabolic agents  | 106 |
| Summary  | 107 |

**Shedding Light on Hypovitaminosis D and Rickets**

By Pallavi Iyer and Frank B. Diamond

|  |     |
|--|-----|
| Biochemistry of vitamin D metabolism             | 116 |
| Bone mineralization and the histology of rickets | 120 |
| Clinical presentations of rickets by age         | 120 |
| Biochemical changes in rickets                   | 122 |
| Roentgenographic diagnosis of rickets            | 122 |
| Perinatal physiology of calcium and vitamin D    | 123 |
| Vitamin D and lactation                          | 124 |

|  |     |
|--|-----|
| Preterm infants  | 125 |
| Hypovitaminosis D and rickets in older children and adolescents                          | 126 |
| The role of calcium deficiency in childhood rickets                                      | 126 |
| Prevention of vitamin D deficiency   | 127 |
| Treatment of nutritional rickets   | 128 |
| Vitamin D's other roles (immunity, blood pressure maintenance,<br>and cancer prevention) | 128 |
| Summary  | 130 |

## **Immunization Update**

By Ayesha Mirza and Mobeen H. Rathore

|   |     |
|---|-----|
| Vaccines for adolescents  | 135 |
| Tetanus, diphtheria toxoids, and pertussis vaccines   | 135 |
| Tetavalent meningococcal conjugate vaccine  | 141 |
| Quadrivalent human papilloma virus vaccine  | 144 |
| New vaccines for children   | 148 |
| Pentavalent (human-bovine) reassortant rotavirus vaccine  | 148 |
| Monovalent human rotavirus vaccine (rotarix HRV:<br>glaxosmithkline)  | 151 |
| Recent changes in the currently recommended immunization<br>Schedule in the united states   | 152 |
| Varicella vaccine   | 152 |
| Quadrivalent mumps, measles, rubella, and varicella vaccine   | 153 |
| Hepatitis a vaccine   | 154 |
| Influenza vaccine   | 155 |
| Other vaccine updates   | 157 |
| Pentavalent combination vaccine (diphtheria, tetanus,<br>acellular pertussis, polio, and haemophilus influenza<br>type b conjugate) | 157 |
| Heptavalent pneumococcal conjugate vaccines   | 158 |
| Summary   | 160 |

## **The Health of Homeless Children Revisited**

By Roy Grant, Alan Shapiro, Sharon Joseph, Sandra Goldsmith,  
 Lourdes Rigual-Lynch, and Irwin Redlener

|                                     |     |
|-------------------------------------|-----|
| Family homelessness in perspective  | 173 |
| Homelessness and child health       | 175 |
| Setting for the study               | 177 |
| Methodology                         | 177 |
| Study results                       | 178 |
| Demographic characteristics         | 178 |
| Immunization status                 | 178 |
| Otitis media                        | 179 |
| Asthma                              | 179 |
| Iron-deficiency anemia              | 180 |
| Overweight and obesity              | 181 |
| Mental health and child development | 181 |
| Summary                             | 183 |

**Children and Megadisasters: Lessons Learned  
in the New Millennium**

By Andrew L. Garrett, Roy Grant, Paula Madrid, Arturo Brito,  
David Abramson, and Irwin Redlener

|   |     |
|---|-----|
| Critical response and recovery issues               | 191 |
| Evacuation  | 191 |
| Obtaining shelter                                   | 196 |
| Children with chronic and special health care needs | 198 |
| Mental health response                              | 200 |
| Summary   | 209 |
| Acknowledgments                                     | 210 |
| Emergency information form for CSHCN                | 211 |

**Dental Caries: State of the Science for the  
Most Common Chronic Disease of Childhood**

By David M. Krol and Michael P. Nedley

|   |     |
|---|-----|
| Taxonomy  | 215 |
| Epidemiology  | 216 |
| General   | 216 |
| Differences in subpopulations of children           | 216 |
| Pathology   | 218 |
| Acquisition and transmission                        | 219 |
| Microbiology  | 220 |
| Prevention  | 221 |
| Risk assessment                                     | 222 |
| Diet and nutrition                                  | 224 |
| Oral hygiene  | 225 |
| Fluoride  | 229 |
| Antibacterials                                      | 231 |
| Xylitol   | 232 |
| Probiotics  | 232 |
| Surgical treatment and a changing paradigm          | 233 |
| The dental home                                     | 233 |
| The role of pediatricians in children's oral health | 234 |

**Atopic Dermatitis**

By Alexander K.C. Leung, K. L. Ellis Hon, and  
Wm. Lane M. Robson

|  |     |
|--|-----|
| Epidemiology                                   | 242 |
| Pathogenesis and etiology                      | 242 |
| Immunopathology                                | 245 |
| Clinical manifestations                        | 245 |
| Diagnosis                                      | 246 |
| Assessment of severity and psychosocial impact | 247 |
| Differential diagnosis                         | 252 |
| Complications                                  | 253 |
| Diagnostic testing                             | 254 |

|   |     |
|---|-----|
| Management  | 255 |
| Patient education                                 | 256 |
| Avoidance of triggering factors                   | 256 |
| Optimal skin care                                 | 257 |
| Topical corticosteroids                           | 258 |
| Systemic immunosuppressants                       | 258 |
| Topical immunomodulators                          | 259 |
| Antihistamines                                    | 262 |
| Antibiotics                                       | 262 |
| Coal tar preparations                             | 262 |
| Phototherapy                                      | 263 |
| Wet-wrap therapy                                  | 263 |
| Probiotics and prebiotics                         | 263 |
| Montelukast                                       | 264 |
| Allergen-specific immunotherapy/hyposensitization | 264 |
| Alternative/complimentary therapies               | 264 |
| Prognosis   | 265 |
| Summary   | 265 |

## **Benefits and Risks of Breastfeeding**

By Armond S. Goldman, Judy M. Hopkinson, and  
David K. Rassin

|  |     |
|--|-----|
| Evolution and milk composition                                   | 275 |
| Health outcomes for the infant                                   | 276 |
| Reduction of morbidity   | 276 |
| Reduction in mortality   | 276 |
| Long-term preventative effects                                   | 277 |
| Infant growth and development                                    | 277 |
| Potential risks associated with breastfeeding                    | 277 |
| Insufficient milk transfer                                       | 278 |
| Deficiencies in micronutrients in human milk                     | 279 |
| Human milk and allergic diseases                                 | 282 |
| Autoimmune diseases and autoantibodies in human milk             | 284 |
| Infectious agents in human milk                                  | 286 |
| Effects of drugs on lactation and drugs in human milk on infants | 289 |
| Pesticides and industrial pollutants in human milk               | 290 |
| Variations in quantities of defense agents in human milk         | 290 |
| Genetic diseases in infancy                                      | 291 |
| Clinical applications: obstacles to be overcome                  | 292 |
| Future studies   | 293 |
| Levels of bioactive agents in human milk                         | 293 |
| Foreign food antigens in human milk                              | 293 |
| Role of enteric commensal flora                                  | 293 |
| HTLV-1 in human milk   | 293 |
| HIV-1 and breastfeeding  | 294 |
| New drugs  | 294 |
| Xenobiotics  | 294 |
| Genetic risks from toxic drugs and xenobiotics                   | 294 |
| Positive effects of human milk                                   | 294 |

|                                    |     |
|------------------------------------|-----|
| CODA                               | 295 |
| Evolution: benefits and risks      | 295 |
| Decision-making by mothers         | 296 |
| Human milk for premature infants   | 296 |
| Laboratory support                 | 296 |
| National and international support | 296 |
| Economics                          | 297 |
| Summary                            | 297 |

|              |            |
|--------------|------------|
| <b>Index</b> | <b>305</b> |
|--------------|------------|